Here's a New Million-Dollar Reason to Buy CRISPR Therapeutics
CRISPR Therapeutics (NASDAQ: CRSP) is heading for an important moment: the potential approval of its first product, exa-cel to treat blood disorders. First, let's talk a little bit about CRISPR's technology. In T1D, the body destroys islet cells that normally would control blood sugar levels.